Hong Kong tightens listing oversight to build lasting trust
Tighter IPO scrutiny by the city’s securities regulators may delay deals but could strengthen investor trust over the longer term By Lee Shih Ta “A market can be competitive…
Cloudbreak Pharma shares halted amid probe into ‘IPO rigging’
Just 14 months after its market debut, the drug developer is under investigation over regulatory concerns that its IPO demand was artificially inflated Key Takeaways: Cloudbreak’s IPO drew strong retail…
Eye drug maker VivaVision feels the strain in IPO funding dash
The developer of new treatments for ocular disorders is in a race against time to secure a Hong Kong listing before its cash reserves run out Key Takeaways: Two VivaVision…
Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
The developer of eye drugs has yet to launch a product on the market and could face financial pressure if its latest listing attempt falters Key Takeaways: Cloudbreak has sold…